Trade Equillium, Inc. - EQ CFD

Equillium, Inc. Company profile

About Equillium Inc

Equillium, Inc. is a clinical-stage biotechnology company. The Company develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The Company's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The Company's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. It also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Equillium Inc revenues was not reported. Net loss increased 31% to $39.1M. Higher net loss reflects Research and development - Balancing val increase of 30% to $24.4M (expense), General and administrative - Balancing increase of 11% to $9M (expense), Other expense, net decrease from $358K (income) to $250K (expense).